NCT00270218View on ClinicalTrials.gov

Safety of and Immune Response to Two Different HIV Vaccines, Each Followed by a Adenoviral Vaccine Boost, in HIV Uninfected Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

February 28, 2006

Study Completion Date

August 31, 2007

Conditions
HIV Infections
Interventions
BIOLOGICAL

VRC-HIVADV014-00-VP

HIV-1 recombinant adenoviral vector vaccine given as a 1 mL intramuscular injection in the deltoid

BIOLOGICAL

VRC-HIVDNA009-00-VP

HIV-1 DNA plasmid vaccine given as a 1 mL intramuscular injection in the deltoid

BIOLOGICAL

FFB

Adenoviral vector FFB given as a 1 mL intramuscular injection in the deltoid

BIOLOGICAL

PBS

phosphate buffered saline

Trial Locations (7)

10003

NY Blood Ctr./Union Square CRS, New York

10032

HIV Prevention & Treatment CRS, New York

37232

Vanderbilt Vaccine CRS, Nashville

94102

San Francisco Vaccine and Prevention CRS, San Francisco

98104

FHCRC/UW Vaccine CRS, Seattle

35294-2041

Alabama Vaccine CRS, Birmingham

14642-0001

Univ. of Rochester HVTN CRS, Rochester

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00270218 - Safety of and Immune Response to Two Different HIV Vaccines, Each Followed by a Adenoviral Vaccine Boost, in HIV Uninfected Adults | Biotech Hunter | Biotech Hunter